Skip to main content
. 2013 Jun 16;15(6):577–589. doi: 10.1007/s10198-013-0495-y

Fig. 6.

Fig. 6

Level of additional benefit compared to % and total number of patients in 39 (Rilpivirine and Emtricitabine/Rilpivirine/Tenofovir disoproxil are referring to the same population) assessed patient subgroups in the 23 (23 from 31 drugs, 4 exempted drugs and 4 drugs without submitted dossier) evaluated EBAs. Total (sum of mean values from G-BA decisions: 1,408,742 patients) (Without the Linagliptin population of 1,219,500 patients due to the dossier re-submission)